Immuneering Corp [NASDAQ: IMRX] plunged by -$0.55 during the normal trading session on while it closed the day at $1.82.
Immuneering Corp stock has also loss -16.13% of its value over the past 7 days. However, IMRX stock has inclined by 8.33% in the 3 months of the year. Over the past six months meanwhile, it has lost -7.61% and lost -17.27% year-on date.
The market cap for IMRX stock reached $65.50 million, with 35.99 million shares outstanding and 25.96 million shares in the current float. Compared to the average trading volume of 241.31K shares, IMRX reached a trading volume of 22438476 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Immuneering Corp [IMRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IMRX shares is $11.08 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IMRX stock is a recommendation set at 1.33. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Immuneering Corp shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on December 13, 2024. While these analysts kept the previous recommendation, Needham dropped their target price from $20 to $15. The new note on the price target was released on March 15, 2024, representing the official price target for Immuneering Corp stock. On March 15, 2024, analysts decreased their price target for IMRX shares from 16 to 3.
The Average True Range (ATR) for Immuneering Corp is set at 0.24 The Price to Book ratio for the last quarter was 1.57, with the Price to Cash per share for the same quarter was set at 1.00.
IMRX stock trade performance evaluation
Immuneering Corp [IMRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -16.13. With this latest performance, IMRX shares gained by 26.39% in over the last four-week period, additionally sinking by -7.61% over the last 6 months – not to mention a rise of 7.69% in the past year of trading.
#####
Immuneering Corp [IMRX]: An insightful look at the core fundamentals
Immuneering Corp’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.48 and a Current Ratio set at 7.48.
Earnings per share (EPS) analysis for Immuneering Corp [IMRX] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IMRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Immuneering Corp go to 3.91%.
Immuneering Corp [IMRX]: Institutional Ownership
The top three institutional holders of IMRX stocks are: CITADEL ADVISORS LLC with ownership of 1.88 million shares, which is approximately 6.4083%. VANGUARD GROUP INC, holding 1.07 million shares of the stock with an approximate value of $$1.37 million in IMRX stocks shares; and VANGUARD GROUP INC, currently with $$1.22 million in IMRX stock with ownership which is approximately 3.2455%.
